Magnetite nanoparticle-loaded anti-HER2 immunoliposomes for combination of antibody therapy with hyperthermia

Cancer Letters

Volumn 212, Issue 2, 2004, Pages 167-175

  Ito, Akira ^a   Kuga, Yuko ^a   Honda, Hiroyuki ^a   Kikkawa, Hiroyuki ^b   Horiuchi, Atsushi ^b   Watanabe, Yuji ^b   Kobayashi, Takeshi ^a  

^a NAGOYA UNIVERSITY   (Japan)

^b EHIME UNIVERSITY   (Japan)

Author keywords

Breast cancer; HER2; Hyperthermia; Immunoliposomes; Magnetite; Magnetite nanoparticles

Indexed keywords

ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR 2 ANTIBODY; IMMUNOLIPOSOME; MAGNETITE; NANOPARTICLE; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL; CONTROLLED STUDY; CYTOTOXICITY; DRUG TARGETING; HEAT TREATMENT; HUMAN; HUMAN CELL; HYPERTHERMIC THERAPY; MAGNETIC FIELD; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL DIVISION; CELL LINE, TUMOR; CELL SURVIVAL; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; FERROSOFERRIC OXIDE; FEVER; HUMANS; IMMUNOTHERAPY; IRON; LIPOSOMES; MAGNETICS; OXIDES; RECEPTOR, ERBB-2; TEMPERATURE; TIME FACTORS;

EID: 3442878768     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2004.03.038     Document Type: Article

References (31)

1. Van der Zee J. Heating the patient: a promising approach? Annu. Oncol. 13:2002;1173-1184
2. Moroz P., Jones S.K., Gray B.N. Magnetically mediated hyperthermia: current status and future directions. Int. J. Hyperthermia. 18:2002;267-284
3. Jordan A., Wust P., Fahling H., John W., Hinz A., Felix R. Inductive heating of ferrimagnetic particles and magnetic fluids: physical evaluation of their potential for hyperthermia. Int. J. Hyperthermia. 9:1993;51-68
4. Minamimura T., Sato H., Kasaoka S., Saito T., Ishizawa S., Takemori S., et al. Tumor regression by inductive hyperthermia combined with hepatic embolization using dextran magnetite-incorporated microspheres, in rats. Int. J. Oncol. 16:2000;1153-1158
5. Shinkai M., Matsui M., Kobayashi T. Heat properties of magnetoliposomes; for local hyperthermia. Jpn. J. Hyperthermic Oncol. 10:1994;168-177
6. Shinkai M., Yanase M., Honda H., Wakabayashi T., Yoshida J., Kobayashi T. Intracellular hyperthermia for cancer using magnetite cationic liposomes: in vitro study. Jpn. J. Cancer Res. 87:1996;1179-1183
7. Yanase M., Shinkai M., Honda H., Wakabayashi T., Yoshida J., Kobayashi T. Intracellular hyperthermia for cancer using magnetite cationic liposomes: ex vivo study. Jpn. J. Cancer Res. 88:1997;630-632
8. Yanase M., Shinkai M., Honda H., Wakabayashi T., Yoshida J., Kobayashi T. Intracellular hyperthermia for cancer using magnetite cationic liposomes: an in vivo study. Jpn. J. Cancer Res. 89:1998;463-469
9. Suzuki M., Shinkai M., Honda H., Kobayashi T. Anticancer effect and immune induction by hyperthermia of malignant melanoma using magnetite cationic liposomes. Melanoma Res. 13:2003;129-135
10. Matsuno H., Tohnai I., Mitsudo K., Hayashi Y., Ito M., Shinkai et al. M. Interstitial hyperthermia using magnetite cationic liposomes to inhibit tumor growth of VX-7 transplanted tumor in rabbit tongue. Jpn. J. Hyperthermic Oncol. 17:2001;141-150
11. Le B., Shinkai M., Kitade T., Honda H., Yoshida J., Wakabayashi T., Kobayashi T. Preparation of tumor-specific magnetoliposomes and their application for hyperthermia. J. Chem. Eng. Jpn. 34:2001;66-72
12. Shinkai M., Le B., Honda H., Yoshikawa K., Shimizu K., Saga S., et al. Targeting hyperthermia for renal cell carcinoma using human MN antigen-specific magnetoliposomes. Jpn. J. Cancer Res. 92:2001;1138-1145
13. Press M.F., Cordon-Cardo C., Slamon D.J. Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene. 5:1990;953-962
14. Lewis G.D., Figari I., Fendly B., Wong W.L., Carter P., Gorman C., Shepard H.M. Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. Cancer Immunol. Immunother. 37:1993;255-263
15. Baselga J., Mendelsohn J. The epidermal growth factor receptor as a target for therapy in breast carcinoma. Breast Cancer Res. Treat. 29:1994;127-138
16. Carter P., Presta L., Gorman C.M., Ridgway J.B., Henner D., Wong W.L., et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc. Natl. Acad. Sci. USA. 89:1992;4285-4289
17. Pegram M., Hsu S., Lewis G., Pietras R., Beryt M., Sliwkowski M., et al. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene. 18:1999;2241-2251
18. Park J.W., Hong K., Carter P., Asgari H., Guo L.Y., Keller G.A., et al. Development of anti-p185HER2 immunoliposomes for cancer therapy. Proc. Natl. Acad. Sci. USA. 92:1995;1327-1331
19. Ito A., Shinkai M., Honda H., Wakabayashi T., Yoshida J., Kobayashi T. Augmentation of MHC class I antigen presentation via heat shock protein expression by hyperthermia. Cancer Immunol. Immunother. 50:2001;515-522
20. Valeriote F., Lin H. Synergistic interaction of anticancer agents: a cellular perspective. Cancer Chemother. Rep. 59:1975;895-900
21. Owen C.S., Sykes N.L. Magnetic labeling and cell sorting. J. Immunol. Methods. 73:1984;41-48
22. Cuello M., Ettenberg S.A., Clark A.S., Keane M.M., Posner R.H., Nau M.M., et al. Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2. Cancer Res. 61:2001;4892-4900
23. Datta S.R., Brunet A., Greenberg M.E. Cellular survival: a play in three Akts. Genes Dev. 13:1999;2905-2927
24. Hancock M.C., Langton, B.C., Chan T., Toy P., Monahan J.J., Mischak R.P., Shawver L.K. A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines. Cancer Res. 51:1991;4575-4580
25. Hudziak R.M., Lewis G.D., Winget M., Fendly B.M., Shepard H.M., Ullrich A. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol. Cell Biol. 9:1989;1165-1172
26. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344:2001;783-792
27. Kano E., Miyakoshi J., Sugahara T. Difference in sensitivities to hyperthermia and ionizing radiation of various mammalian cell stress in vitro. Streffer C., van Beuninen D., Dietzel F., Rottinger E., Robinson J.E., Scherer E., Seeber S., Trott K.R. Cancer therapy by hyperthermia and radiation. 1978;188-190 Urban and Schwarzenberg, Baltimore-Munich
28. Kano E., Miyakoshi J., Furukawa M., Kato H., Ohsaki S., Nishida T., Heki S. Effects of hyperthermia at 50°C on V-79 cells in vitro. J. Radiat. Res. (Tokyo). 23:1982;218-227
29. Hamm B., Staks T., Taupitz M., Maibauer R., Speidel A., Huppertz A., et al. Contrast-enhanced MR imaging of liver and spleen: first experience in humans with a new superparamagnetic iron oxide. J. Magn. Reson. Imaging. 4:1994;659-668
30. Stark D.D., Weissleder R., Elizondo G., Hahn P.F., Saini S., Todd L.E., et al. Superparamagnetic iron oxide: clinical application as a contrast agent for MR imaging of the liver. Radiology. 168:1988;297-301
31. Suzuki M., Honda H., Kobayashi T., Wakabayashi T., Yoshida J., Takahashi A. Development of a target-directed magnetic resonance contrast agent using monoclonal antibody-conjugated magnetic particles. Brain Tumor Pathol. 13:1996;127-132